<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300742</url>
  </required_header>
  <id_info>
    <org_study_id>12069</org_study_id>
    <nct_id>NCT00300742</nct_id>
  </id_info>
  <brief_title>Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals</brief_title>
  <official_title>Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individual</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the feasibility of using topiramate to reduce binge
      eating and drinking episodes in alcohol dependent individuals with comorbid binge eating
      disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research has shown an alarming coincidence of binge eaters also reporting serious alcohol
      abuse. Evidence has shown this population to have higher rates of psychiatric comorbidity,
      higher caloric intakes during meals, higher rates of tobacco use, more frequent binge
      episodes, and an earlier age of onset for binge eating and alcohol abuse. It is believed that
      topiramate may reduce binge eating and has been found helpful in reducing the cravings
      associated with alcohol consumption.

      This study is to test the feasibility of administering topiramate to individuals with alcohol
      dependence and binge eating disorder. This will involve determining the adequacy of the
      amount of assessment and scheduled visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance With Study Requirements: Attendance at Treatment Sessions</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Drinks Per Day at Baseline vs. Visit 12</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Mean drinks per day at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Days Abstinent Per Week at Baseline vs. Visit 12</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Mean percent days abstinent per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Binge Eating Episodes Per Week at Baseline vs. Visit 12</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Mean binge eating episodes per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance With Study Requirements: Topiramate Level</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Number of subjects who escalated to the maximum dose of 300 mg of topiramate/day</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Binge Eating</condition>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Topiramate Other Name for Topiramate: Topamax</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Topiramate up to 300 mg per day.</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females that have given written informed consent.

          -  Good physical health as confirmed by a complete physical examination, vital signs
             including an EKG within normal limits, laboratory screening tests within acceptable
             parameters (see exclusion criteria), as well as a baseline psychiatric history

          -  Diagnosis of alcohol dependence and binge eating disorder.

          -  Subjects must have 3 or more binge days per week in the 2-week period prior to Screen.

          -  Subjects may have uncomplicated and well-controlled Type II diabetes and/or
             hypertension that has been well controlled by diet and/or oral agent therapy for at
             least 3 months prior to screen.

          -  Provide evidence of stable residence in the last month.

          -  The pregnancy test for females at intake must be negative. The female patients must
             either be sterile, post menopausal, or practicing an acceptable form of contraception.

          -  Literate in English and able to read, understand, and complete the ratings scales and
             questionnaires accurately, follow instructions, and make use of the behavioral
             treatment.

          -  Subjects must have signed an informed consent document indicating that they understand
             the purpose of and procedures required for the study and are willing to participate in
             the study.

        Exclusion Criteria:

          -  Any current DSM-IV psychiatric diagnosis other than alcohol, nicotine dependence or
             binge eating disorder

          -  Subjects who have begun to receive formal psychotherapy (cognitive-behavioral therapy,
             interpersonal therapy, dietary behavioral therapy*, or self-guided
             cognitive-behavioral) for binge-eating disorder or any other psychiatric disorder
             within 30 days prior to Screen. Subjects who have been engaged in formal psychotherapy
             for a longer period of time and plan to maintain therapy will be judged on a
             case-by-case basis.

               -  Formal dietary behavioral therapy applies to therapy where the subject is
                  diagnosed with an eating disorder and/or the health case provider is billing for
                  costs of therapy (will be considered on a case-by-case basis if started within 30
                  days of Screen. Subjects engaged in dietary for obesity only (e.g., Jenny Craig,
                  Weight Watchers, Overeater's Anonymous) should discontinue therapy prior to study
                  entry (no washout applies).

          -  Clinically significant laboratory screening test.

          -  Clinically significant cardiovascular disease on a 12 lead EKG.

          -  Symptomatic coronary artery disease or peripheral vascular disease.

          -  Malignancy or history of malignancy within the past 5 years (except basal cell
             carcinoma).

          -  Clinically significant neurological disease.

          -  Clinically significant renal disease or impaired renal function as defined by subjects
             with an estimated creatinine clearance of less than 60 mL/min.

          -  Severe withdrawal symptoms which in the physicians' opinion requires inpatient
             treatment or severe or life-threatening adverse reactions to medications either in the
             past or during this clinical trial.

          -  Female patients who are pregnant, lactating, or not adhering to an acceptable form of
             contraception at any time during the study.

          -  Members of the same household.

          -  History of severe hypersensitivity to any medication or environmental allergens.

          -  Subjects with prior non-response to topiramate for the treatment of binge-eating and
             or alcohol disorder following an adequate trial of this medication

          -  Subjects who have been previously treated with topiramate for any reason and
             discontinued treatment due to an adverse event or due to a hypersensitivity reaction
             to topiramate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nassima Ait-Daoud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia, Department of Psychiatric Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UVA CARE</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVA CARE Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2006</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>March 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2017</results_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Nassima Ait-Daoud Tiouririne</investigator_full_name>
    <investigator_title>Associate Professor, Director of UVA Center for Addiction Research and Education</investigator_title>
  </responsible_party>
  <keyword>drinking</keyword>
  <keyword>eating</keyword>
  <keyword>obesity</keyword>
  <keyword>alcohol</keyword>
  <keyword>binge eating</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
    <mesh_term>Bulimia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in Charlottesville and Richmond between September 2006 to February 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Topiramate/BBCET</title>
          <description>Escalating dose of up to 300 mg/day of Topiramate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topiramate/BBCET</title>
          <description>Escalating dose of up to 300 mg/day of Topiramate</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="10.46422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Compliance With Study Requirements: Attendance at Treatment Sessions</title>
        <time_frame>up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate/BBCET</title>
            <description>Patients receiving an escalating dose of up to 300 mg/day of Topiramate, plus BBCET (Brief Behavioral Compliance Enhancement Treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With Study Requirements: Attendance at Treatment Sessions</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects completed through Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects completed through Visit 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Drinks Per Day at Baseline vs. Visit 12</title>
        <description>Mean drinks per day at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate/BBCET</title>
            <description>Escalating dose of up to 300 mg/day of Topiramate, plus BBCET (Brief Behavioral Compliance Enhancement Treatment)at 12 weekly visits following the initial baseline and randomization visits</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Drinks Per Day at Baseline vs. Visit 12</title>
          <description>Mean drinks per day at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
          <population>Per protocol</population>
          <units>Drinks/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean drinks per day at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.95" spread="13.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean drinks per day at Visit 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Days Abstinent Per Week at Baseline vs. Visit 12</title>
        <description>Mean percent days abstinent per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate/BBCET</title>
            <description>Escalating dose of up to 300 mg/day of Topiramate, plus BBCET (Brief Behavioral Compliance Enhancement Treatment)at 12 weekly visits following the initial baseline and randomization visits</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Days Abstinent Per Week at Baseline vs. Visit 12</title>
          <description>Mean percent days abstinent per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
          <population>Per protocol</population>
          <units>Mean percent days abstinent per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean percent days abstinent per week at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="21.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean percent days abstinent per week at Visit 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Binge Eating Episodes Per Week at Baseline vs. Visit 12</title>
        <description>Mean binge eating episodes per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate/BBCET</title>
            <description>Escalating dose of up to 300 mg/day of Topiramate, plus BBCET (Brief Behavioral Compliance Enhancement Treatment)at 12 weekly visits following the initial baseline and randomization visits</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Binge Eating Episodes Per Week at Baseline vs. Visit 12</title>
          <description>Mean binge eating episodes per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
          <population>Per protocol</population>
          <units>Binge eating episodes/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean weekly binge eating episodes at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean weekly binge eating episodes at Visit 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Compliance With Study Requirements: Topiramate Level</title>
        <description>Number of subjects who escalated to the maximum dose of 300 mg of topiramate/day</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>This is the number of participants who reached the dose of 300 mg of topiramate</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate/BBCET</title>
            <description>Patients receiving an escalating dose of up to 300 mg/day of Topiramate, plus BBCET (Brief Behavioral Compliance Enhancement Treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With Study Requirements: Topiramate Level</title>
          <description>Number of subjects who escalated to the maximum dose of 300 mg of topiramate/day</description>
          <population>This is the number of participants who reached the dose of 300 mg of topiramate</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Topiramate/BBCET</title>
          <description>Escalating dose of up to 300 mg/day of Topiramate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nassima Ait-Daoud</name_or_title>
      <organization>UVA Center for Addiction Research and Education</organization>
      <phone>434-243-0541</phone>
      <email>uvacare@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

